Investorideas.com

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Medical Tech Stock News: ScreenPro (CSE: SCRN) Announces Expansion of Mobile COVID-19 Testing Units Division
Toronto, Ontario - January 14, 2022 (Newsfile Corp.) (Investorideas.com Newswire) ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to announce that the Company is expanding newly deployed mobile testing units in Greater Vancouver and Greater Toronto Area.

Ph1 Trial Results of Dementia Drug Positive
January 13, 2022 (Investorideas.com Newswire) Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints

Biotech Co. Partners With Life Sciences Firms
January 12, 2022 (Investorideas.com Newswire) 2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed

Enrollment Done for COVID-19 Drug Trial
January 11, 2022 (Investorideas.com Newswire) Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway

2022 to be Catalyst Rich for Biopharma
January 11, 2022 (Investorideas.com Newswire) The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies

BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants
MAINZ, Germany and LONDON, United Kingdom - January 11, 2022 (Investorideas.com Newswire) BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd ("InstaDeep") today announced the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2.

Co.'s samRNA Vaccines Protect Better Against COVID Variants
January 10, 2022 (Investorideas.com Newswire) Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants.

Co. Partners to Test New Cancer Vaccines
January 7, 2022 (Investorideas.com Newswire) Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens in potential vaccine therapies for cancer.

Co. Plans to Make 100M Rapid COVID Tests Monthly
January 6, 2022 (Investorideas.com Newswire) Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif.

Analyst: Drug a 'Hidden Gem for 2022'
January 3, 2022 (Investorideas.com Newswire) Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Guest Posts - Ideas from Contributors

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

GEGR Metro VR Studio Joint Venture Agreement with School Responders
Salt Lake City, Utah--(Newsfile Corp. - January 18, 2022) - Gaensel Energy Group, Inc., (OTC Pink: GEGR) ("Gaensel" or the "Company"), a diversified holding company is pleased to release Metro VR Studios' news!Metro VR Studios of Boston, Massachusetts, https://metrovrstudios.com, and School Responder, https://www.SchoolResponder.com, of Lancaster, Pennsylvania, announced a Metaverse-based, joint development agreement. The partnership will result in a VR/MR communication process and EdTech system that enhances student health, wellness and safety.The ground-breaking platforms...

Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health
Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, submitted results for its multicenter, Phase-II clinical trial to the Israeli Ministry of Health on January 9th. Following on the heels of the Company's initial release of encouraging preliminary results in November 2021, the trial data submitted last week further demonstrate...

The Well Told Company Announces Promotion of Betty Au Yeung, CPA, CGMA, to Position of CFO and Corporate Secretary
Toronto, Ontario--(Newsfile Corp. - January 18, 2022) - The Well Told Company Inc. (TSXV: WLCO) (FSE: 7HO) ("Well Told" or ‎the "Company"), the female-founded wellness company that offers plant-‎based supplements, remedies, and other functional wellness products, is pleased to announce the appointment of Betty Au Yeung, CPA, CGMA, to the role of Chief Financial Officer (CFO) and Corporate Secretary.Monica Ruffo, founder and CEO of Well Told, stated, "Betty joined Well Told in July 2021 and...

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test Kit

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced an agreement with Psychedelics Today, LLC ("Psychedelics Today'') to help drive brand awareness of the Company's Psychedelics Genetic Test Kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life...

Zonetail Engages Global Edge Investments to Run the "Playbook"
Toronto, Ontario--(Newsfile Corp. - January 18, 2022) - Zonetail Inc. (TSXV: ZONE) (OTCQB: ZTLLF) ("Zonetail" or the "Company") announces it has engaged Global Edge Investments Inc. ("GEI") to assist the Company in executing its comprehensive new strategy, blueprint and playbook for the burgeoning and lucrative condo and multi-family rental/apartment markets.The new blueprint and playbook perfectly positions Zonetail to be a dynamic Market Network. Market Networks combine elements of network platforms with marketplaces and are producing a...

Subscribe to Biotech News